Has Teva faced pay-for-delay allegations?
Yes — Teva was co-defendant with Gilead in a $3.6 billion antitrust case over a 2014 settlement that allegedly delayed generic HIV drugs, but a June 2023 federal jury found both companies not liable.
Yes, though it prevailed at trial. Teva was a co-defendant with Gilead in a $3.6 billion antitrust case alleging that a 2014 patent settlement delayed generic versions of the HIV drugs Truvada and Atripla. The plaintiffs claimed Teva had effectively received a reverse payment to delay entry.
In June 2023 a federal jury in California found Gilead and Teva not liable, concluding the plaintiffs had not shown that Gilead had market power or that it paid Teva to delay. The case is included here because the allegations were serious and widely publicised, but readers should note the verdict: pay-for-delay claims against Teva in this case were rejected. Teva's generic Truvada eventually launched in October 2020.